- Halozyme Therapeutics (HALO +2.1%) is up on average volume on the heels of its initiation of a Phase 1 clinical trial assessing the combination of PEGPH20 (pegvorhyaluronidase alfa) and Roche's (OTCQX:RHHBY -0.6%) TECENTRIQ (atezolizumab) in patients with metastatic cholangiocarcinoma (bile duct cancer) and gallbladder adenocarcinoma.
- The Phase 1b/2 open-label study will compare the combination with standard chemo (cisplatin and gemcitabine). According to ClinicalTrials.gov, the estimated primary completion date is March 2020.
- PEGPH20 is an investigational drug administered intravenously that temporarily degrades hyaluronan, a chain of natural sugars that builds up around cancer cells inhibiting the effectiveness of cancer-killing therapies.
- Previously: Halozyme up 1% premarket on start of Roche study of PEGPH20/Tecentriq combo in pancreatic cancer (July 13)
- Now read: Halozyme Therapeutics (HALO) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
Original article